[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"interventional-cardiology\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:interventional-cardiology":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100615756","pivotal-study-of-the-supira-system-in-patients-undergoing-high-risk-percutaneous-coronary-intervention-hrpci-100615756",false,"NCT07296744","Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)","Pivotal Randomized Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)","SUPPORT II","Inclusion Criteria:\n\n* Hemodynamically stable and will undergo elective or urgent (not emergent) HRPCI, where hemodynamic support is deemed necessary, as determined by the institutional Heart Team\n* Informed consent granted by the subject or legally authorized representative\n\nExclusion Criteria:\n\n* Cardiogenic shock or acutely decompensated pre-existing chronic heart failure\n* Stroke within 6 months of the index procedure, or any prior stroke with permanent neurologic deficit\n* Left ventricular thrombus\n* Aortic and iliofemoral anatomical conditions that preclude safe delivery and placement of the investigational device or the comparator device\n* Ongoing renal replacement therapy with dialysis\n* Presence of decompensated liver disease; severe liver dysfunction\n* Infection of the proposed procedural access site or active infection\n* Known hypersensitivity to intravenous contrast agents that cannot be adequately pre-medicated or known hypersensitivity to heparin, aspirin, adenosine diphosphate (ADP) receptor inhibitors, or nitinol\n* Any condition, coagulopathy, planned procedure or contraindication that requires discontinuation of antiplatelet and\u002For anticoagulant therapy within 90 days of the index procedure\n* Breastfeeding or pregnant or planning to become pregnant within 90 days of the HRPCI procedure\n* Currently participating in active follow-up phase of another clinical study of an investigational drug or device or planning to enroll in such a study within 90 days of the HRPCI procedure\n* Other medical, social, or psychological problems that, in the opinion of the Investigator, compromises the subject's ability to provide written informed consent and\u002For to comply with study procedures\n* Considered to be part of a vulnerable population per the investigator's assessment","ALL","18 Years","90 Years",{"count":21,"type":22},358,"ESTIMATED","INTERVENTIONAL",[25],"NA","The objective of this study is to assess the safety and efficacy of the Supira System in providing temporary cardiovascular hemodynamic support in patients undergoing HRPCI. Eligible patients will be randomized to undergo HRPCI with either the Supira System (investigational device) or the commercially available Impella systems (comparator device).",[28,29,30,31],"Coronary Artery Disease","High Risk Percutaneous Coronary Intervention","Interventional Cardiology","Mechanical Circulatory Support",[33,34,31,35],"Percutaneous ventricular assist device","Supira System","US Pivotal","RECRUITING","2026-06-10",{"date":39,"type":40},"2026-06-11","ACTUAL",{"date":42,"type":40},"2026-05-11",{"date":44,"type":22},"2027-11",{"name":46,"class":47},"Supira Medical","INDUSTRY",14,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100601584","pressure-volume-loop-assessment-in-valvular-heart-disease-100601584","NCT07112391","Pressure-Volume Loop Assessment in Valvular Heart Disease","Invasive Hemodynamic Study of Structural Heart Diseases: A Monocentric, Non-Randomized Approach","VHD-PV-loop","Inclusion Criteria:\n\n* Adult patients (≥ 18 years old);\n* Patients with severe structural heart disease (meeting at least one of the following three criteria):\n\n  * Heart failure with moderate-to-severe or severe secondary mitral regurgitation\n  * At least severe tricuspid regurgitation\n  * Significant pulmonary valve stenosis and\u002For regurgitation\n\nExclusion Criteria:\n\n* Patients under legal guardianship or protection (e.g., guardianship, trusteeship, or any other legal protection measure);\n* Pregnant or breastfeeding women;\n* Vulnerable individuals (e.g., persons deprived of liberty, adults under legal protection);\n* Contraindication to right heart catheterization, including:\n\n  * Known proximal venous occlusion of the superior or inferior vena cava territory\n  * Presence of a mobile mass in the right heart chambers\n  * Significant tricuspid stenosis",{"count":58,"type":22},70,"OBSERVATIONAL","The VHD PV loop study intends to assess invasive right ventricular to pulmonary artery (RV-PA) coupling in patients with valvular heart disease (VHD). Invasive RV-PA coupling is measured by using conductance catheters, the gold standard assessment for ventricular physiology. Several non-invasive parameters have been reported as surrogates for this complex physiological entity, but none of them has been tested against the gold-standard in this population. Based on this, our main objective is to assess the correlation of imaging derived RV-PA coupling in comparison to the invasive measurement.",[62,63,30],"Heart Failure","Structural Heart Disease",[65,66,67,68],"Chronic heart failure","Structural heart disease","Interventional cardiology","Multimodality imaging","2025-09-09",{"date":71,"type":40},"2025-09-16",{"date":73,"type":40},"2025-09-04",{"date":75,"type":22},"2027-09-04",{"name":77,"class":78},"Nantes University Hospital","OTHER",1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":79},"100380995","phase-4-ticagrelor-with-low-dose-versus-regular-aspirin-in-patients-with-acute-coronary-syndrome-acs-at-high-risk-for-ischemia-after-percutaneous-coronary-intervention-100380995","NCT04240834","Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention","Safety and Efficacy of Ticagrelor With Low-dose Aspirin Versus Regular Aspirin in Patients With Acute Coronary Syndrome at High-risk for Ischemia After Percutaneous Coronary Intervention: A Randomized Controlled Study","LD-ASPIRIN","Inclusion Criteria:\n\n* ACS patients at high risk for ischemic events after successful PCI with implantation of at least one drug eluting stent\n* Able and willing to provide informed consent and participate in 12 months follow-up period\n* Able to receive DAPT treatment\n* Enrollment into the study will require meeting at least one angiographic or clinical inclusion and none of the exclusion criteria.\n\nClinical inclusion criteria:\n\n1. Family history of premature coronary heart disease (Coronary heart disease in first-degree male relative \\\u003C55 years old or in first-degree female relative \\\u003C65 years old)\n2. Repeated myocardial infarction\n3. Positive serum cardiac troponin I\u002FT\n4. Combined with at least one organ\u002Fsystem with atherosclerotic disease (e.g. intracranial or peripheral arteries)\n5. Type 2 diabetes mellitus under medication\n6. Chronic kidney disease (eGFR\\\u003C60 mL\u002Fmin\u002F1.73 m2 or CrCl\\\u003C60ml\u002Fmin)\n\nAngiographic Inclusion Criteria:\n\n1. LM lesion requiring stents\n2. Proximal LAD lesion(s) requiring stents\n3. Bypass grafts lesion(s) requiring stents\n4. Overall stent length ≥60 mm\n5. History of in-stent thrombosis\n6. Bifurcation lesions requiring at least 2 stents\n7. Over two vessels lesions requiring stents\n8. Calcified target lesion(s) requiring atherectomy\n9. The intraoperative occurrence of no-reflow or slow-flow\n10. Compressed branch vessels with a diameter of at least 2.0 mm failing to reach flow restoration (at least TIMI 3)\n\nExclusion Criteria:\n\n* Need for chronic oral anticoagulation\n* With cardiomyopathy（HCM\u002FDCM\u002FRCM）\n* With severe ventricular arrhythmia requiring ICD implantation\n* With chronic respiratory disease (COPD, asthma, chronic bronchitis, pulmonary heart disease)\n* With severe infectious disease（active hepatitis B, active hepatitis C, AIDS）\n* With hematological disorders（thrombocytopenia, severe anemia, leukaemia）\n* With severe liver disease or kidney failure\n* With malignant tumor\n* With cognitive impairment\n* Unable or unwilling to provide informed consent or undergo follow-up",{"count":89,"type":22},1220,[91],"PHASE4","The present study is aimed to compare the safety and efficacy of Ticagrelor with low-dose Aspirin versus standard dual anti-platelet therapy (DAPT) in patients with acute coronary syndrome (ACS) at high risk for ischemic events after percutaneous coronary intervention (PCI) and stent implantation.",[94,30],"Acute Coronary Syndrome",[96,97,98,99,100],"ACS","PCI","DAPI","Aspirin","Ticagrelor","2024-06-15",{"date":103,"type":40},"2024-06-18",{"date":105,"type":40},"2021-02-01",{"date":107,"type":22},"2026-12",{"name":109,"class":78},"Fu Wai Hospital, Beijing, China"]